Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
signs and symptoms pathological conditions | D013568 |
Brand Name | Status | Last Update |
---|---|---|
isoptin sr | 2008-03-11 | |
tarka | New Drug Application | 2012-02-13 |
trandolapril and verapamil hydrochloride | ANDA | 2019-09-30 |
verapamil | ANDA | 2011-08-11 |
verapamil hydrochloride | ANDA | 2014-05-27 |
verapamil hci | New Drug Application | 2024-02-26 |
verapamil hcl | ANDA | 2019-06-03 |
verapamil hydrochloride | NDA authorized generic | 2025-03-25 |
verapamil hydrochloridepm | ANDA | 2010-06-04 |
verelan | New Drug Application | 2023-02-22 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Drug common name | Verapamil |
INN | verapamil |
Description | 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile is a tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. It is a tertiary amino compound, an aromatic ether, a polyether and a nitrile. |
Classification | Small molecule |
Drug class | coronary vasodilators (verapamil type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC |
PDB | — |
CAS-ID | 52-53-9 |
RxCUI | — |
ChEMBL ID | CHEMBL6966 |
ChEBI ID | 77733 |
PubChem CID | 2520 |
DrugBank | DB00661 |
UNII ID | CJ0O37KU29 (ChemIDplus, GSRS) |